Navigation Links
Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkin's Lymphoma
Date:2/20/2008

atment of patients with mantle cell lymphoma who have received at least one prior therapy. VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol. VELCADE should be administered under the supervision of a physician experienced in the use of antineoplastic therapy. In the European Union and many other countries worldwide, VELCADE is approved for patients with multiple myeloma after first relapse.

Risks associated with VELCADE therapy include new or worsening peripheral neuropathy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. Acute development or exacerbation of congestive heart failure, and/or new onset of decreased left ventricular ejection fraction has been reported, including reports in patients with few or no risk factors for decreased left ventricular ejection fraction. There have been rare reports of acute diffuse infiltrative pulmonary disease of unknown etiology such as pneumonitis, interstitial pneumonia, lung infiltration and Acute Respiratory Distress Syndrome in patients receiving VELCADE. Some of these events have been fatal. A higher proportion of these events have been reported in Japan. There have been rare reports of Reversible Posterior Leukoencephalopathy Syndrome (RPLS) in patients receiving VELCADE. RPLS is a rare, reversible, neurological disorder which can present with seizure, hypertension, headache, lethargy, confusion, blindness, and other visual and neurological disturbances. VELCADE is associated with thrombocytopenia and neutropenia. There have been reports of gastrointestinal and intracerebral hemorrhage in associa
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
2. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
3. VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome
4. Cellectar Expands Clinical Management Team
5. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
6. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
7. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
8. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
9. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
10. Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies
11. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... , May 29, 2015 Educating ... of the Association for the Advancement of Wound ... With support from AAWC,s corporate partners, the ... Portal on the AAWC website at ... wound care pathway with links to various CME/CEU ...
(Date:5/28/2015)... 28, 2015 Research ... addition of Jain PharmaBiotech,s new report  "RNAi ... their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... silencing involves the use of double stranded ... material is processed into short 21-23 nucleotide ...
(Date:5/28/2015)... The controversy surrounding the use of ... (procedures to remove uterine fibroids) continues, as a ... Johnson & Johnson,s Ethicon, Inc. unit, which was ... to the report published by The Wall Street ... is trying to determine what the company knew ...
Breaking Medicine Technology:The Association for the Advancement of Wound Care Educates the Public 2Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 2Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 3Power Morcellator Attorneys at Bernstein Liebhard LLP Comment on Report That FBI Is Investigating Ethicon Morcellators 2Power Morcellator Attorneys at Bernstein Liebhard LLP Comment on Report That FBI Is Investigating Ethicon Morcellators 3
... , PHILADELPHIA , Jan. 26 ... has licensed LiquentConnect® - a hosted software as ... review, amend and submit regulatory dossiers.  Omnicare Clinical Research is ... serving the biopharmaceutical and medical device industries. , LiquentConnect ...
... WORTH, Texas and PETERBOROUGH, Ontario , Jan. ... marketing Collagenase SANTYL® Ointment to healthcare professionals in Canada ... debriding chronic dermal ulcers (e.g., pressure ulcers, vascular ulcers, and ... only enzymatic debrider available in the Canadian market. , ...
Cached Medicine Technology:Omnicare Clinical Research Licenses LiquentConnect to Create Added Value for Clients 2Omnicare Clinical Research Licenses LiquentConnect to Create Added Value for Clients 3Healthpoint Launches Collagenase SANTYL(R) Ointment in Canada 2Healthpoint Launches Collagenase SANTYL(R) Ointment in Canada 3
(Date:5/29/2015)... 29, 2015 M3 USA MDLinx.com, source ... 14 medical specialties, now offers The Smartest Rheumatologist ... of rheumatology disorders ranging from Fibromyalgia and Osteoporosis, to ... director of MDLinx, and Caroline Tredway, editorial head of ... it will have on the physicians who participate. Says ...
(Date:5/29/2015)... 2015 Abington Hospital – Jefferson ... first hospitals in the nation to join the ... practices and work toward achieving the Baby-Friendly USA© ... focusing on maternity care practices leading to Baby-Friendly ... and Prevention, EMPower is aimed at increasing breastfeeding ...
(Date:5/29/2015)... Dot Hill can mark one more item off her bucket ... Woods retirement community is the oldest woman to have flown ... was great fun!”, she exclaimed. “I’ve always wanted to jump ... they thought this would be ok.” , “We put on nylon ... she described. “I don’t remember it being noisy, but the ...
(Date:5/29/2015)... North Carolina (PRWEB) May 29, 2015 ... confirmed that the newest Red Hot & Blue restaurant at ... business on Thursday, May 7, 2015. “The Red Hot & ... center for 18 years, but we have moved to a ... are now in the middle of all the activities on ...
(Date:5/29/2015)... 2015 Johnson & Johnson and ... Risperdal lawsuit ( http://www.risperdallawsuit2014.com/ ) settlement with a ... his use of the antipsychotic medication. According to ... the third bellwether trial to involve male breast ... in Pennsylvania’s Philadelphia Court of Common Pleas, where ...
Breaking Medicine News(10 mins):Health News:MDLinx Launches Smartest Rheumatologist 2Health News:Abington Hospital Selected to Join Baby-Friendly Hospital Initiative 2Health News:Indoor Skydiving Brings Thrills to Seniors 2Health News:Red Hot & Blue Restaurant Opens in Cary, North Carolina 2Health News:Red Hot & Blue Restaurant Opens in Cary, North Carolina 3Health News:Red Hot & Blue Restaurant Opens in Cary, North Carolina 4Health News:Risperdal Lawsuit Selected as Pennsylvania’s Third Bellwether Gynecomastia Case Settles Hours Before Trial 2Health News:Risperdal Lawsuit Selected as Pennsylvania’s Third Bellwether Gynecomastia Case Settles Hours Before Trial 3
... Despite the popularity of colon cleansing, there,s no evidence ... or in day spas -- offers any health benefits, a ... side effects ranging from vomiting to kidney failure and death, ... also called colonic irrigation or colonic hydrotherapy -- often involves ...
... WASHINGTON, Aug. 1Researchers at the Massachusetts Institute of Technology ... high-speed, three-dimensional (3-D) imaging of microscopic pre-cancerous changes in ... the Optical Society,s (OSA) open access journal Biomedical ... called optical coherence tomography (OCT), which offers a way ...
... is a mysterious developmental disease because it often leaves ... example, it is well documented that autistic children often ... as "you" instead of "I." A new brain ... by scientists at Carnegie Mellon University provides an explanation ...
... -- A new study seems to confirm the widely held ... e-mails, social media and news. Researchers analyzed the habits ... found that they checked their devices throughout their waking hours. ... opening the screen lock and accessing a single application. ...
... Alexandria, VA - The 2011 Annual Meeting & OTO ... and Neck Surgery Foundation (AAO-HNSF), the largest meeting of ... convene September 11-14, 2011 in San Francisco, CA. ... and several hundred instruction course hours for attendees, the ...
... dietary counseling for obesity are heavily rooted in the ... ability to choose healthy foods and portion sizes consistent ... According to preventive medicine and behavioral ... new counseling approach that views obesity as a result ...
Cached Medicine News:Health News:Colon Cleansing Has No Health Benefit, May Harm: Report 2Health News:New high-speed 3-D imaging system holds potential for improved cancer screening 2Health News:New high-speed 3-D imaging system holds potential for improved cancer screening 3Health News:New high-speed 3-D imaging system holds potential for improved cancer screening 4Health News:New CMU brain imaging research reveals why autistic individuals confuse pronouns 2Health News:New CMU brain imaging research reveals why autistic individuals confuse pronouns 3Health News:Smartphones Really Are Habit-Forming: Study 2Health News:World's largest meeting of ear, nose and throat doctors 2Health News:Obesity counseling should focus on neurobehavioral processes, not personal choice, researchers say 2Health News:Obesity counseling should focus on neurobehavioral processes, not personal choice, researchers say 3
MAXM is a reliable benchtop solution for processing mid-size volume workloads. Features include three-dimensional VCS technology, continuous autoloading and easy-to-use data management capabilities....
... The LH 755 simplifies ... by integrating expert automation and ... It delivers reliable, accurate results ... the best slide quality with ...
Creatinine Test Kit (enzymatic, liquid reagents), Wavelength: 550 nm. Linear range: up to 150 mg/dL....
Kinetic and endpoint methods for the quantitative determination of creatinine in serum....
Medicine Products: